Clinical trials
SGLT 2 Inhibitors clinical trials
Below are recruiting sglt 2 inhibitors clinical trials, each written for real people, not researchers. We’re tracking 10 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05029115Enrolling by invitation
SGLT2 pill study for atrial fibrillation with type 2 diabetes
This trial tests whether an SGLT2 inhibitor pill can help people who have atrial fibrillation (an irregular heartbeat) and type 2 diabetes. You may be eligible if you’re in the right age range, on diabetes pills only, and meet specific heart and lab criteria.
Yangcheon, SeoulAges 20–80 - NCT07292909RecruitingPhase 4
Effect of Empagliflozin on Inflammation for Coronary Patients
This trial tests if the diabetes drug empagliflozin can help reduce inflammation in people with stable coronary artery disease who are planning to have a stent placed. It may offer a new way to protect heart health.
Beirut, BeirutAges 18 years+ - NCT07143773RecruitingPhase 4
SGLT2i safety in kidney transplant patients without diabetes
This study tests whether a medicine called SGLT2i (a type of pill for kidney health) is safe and helpful for kidney transplant recipients who do not have diabetes. It aims to see if it can improve how the new kidney works.
OdenseAges 18 years+ - NCT06838286Recruiting
Study of triple therapy for type 2 diabetes
This study looks at the safety and effectiveness of adding a third oral diabetes medicine to your current two-drug combination. It is for adults with type 2 diabetes whose blood sugar is not well controlled on metformin plus one other pill.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT06863532Recruiting
Comparing two add-on treatments for type 2 diabetes
This trial compares adding a new pill (cofrogliptin) to increasing your current metformin dose, for people whose blood sugar is still too high despite taking an SGLT2 inhibitor and a low dose of metformin. The goal is to see which option works better and is safer.
Hangzhou, ZhejiangAges 18–74 - NCT05305911RecruitingPhase 2
SGLT2 drug after first heart attack to reduce heart damage
This Phase 2 trial tests whether an SGLT2 medicine started after a first STEMI heart attack can reduce ongoing heart muscle injury and scarring. It may help people who, based on heart imaging, have larger infarcts and ongoing microvascular damage.
Minneapolis, MinnesotaAges 18–75 - NCT06433050RecruitingEarly Phase 1
Testing a diabetes drug for nonobstructive hypertrophic cardiomyopathy
This trial tests a common diabetes drug (SGLT2 inhibitor) to see if it helps people with nonobstructive hypertrophic cardiomyopathy (HCM). The medicine may improve how your heart works and how well you can exercise.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07070765Recruiting
Study on dapagliflozin to protect the heart during breast cancer chemo
This trial tests if a heart-protecting drug called dapagliflozin can help prevent heart damage in breast cancer patients receiving a type of chemotherapy called anthracycline. It may be an option if you have low to medium heart risk factors.
Aberdeen, AberdeenshireAges 18–70 - NCT04899479RecruitingPhase 4
SGLT-2 inhibitor after heart attack to improve heart recovery
This trial studies whether starting an SGLT-2 inhibitor around the time of a heart attack can reduce heart damage size and improve how the heart heals. It focuses on people with a high risk of developing heart failure and who are getting a procedure to open blocked heart arteries.
SeoulAges 18 years+ - NCT07076823RecruitingPhase 1
Canagliflozin for MSI-H colorectal cancer
This trial tests a diabetes drug, canagliflozin, for people with a specific type of colorectal cancer (MSI-H). It's for those whose cancer has continued to grow after at least two standard treatments.
Chengdu, SichuanAges 18–80
Hear when a new SGLT 2 Inhibitors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sglt 2 inhibitors?
- Yes. Clin2 currently lists 10 recruiting sglt 2 inhibitors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sglt 2 inhibitors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sglt 2 inhibitors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.